Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2017-01-01
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
NCT04573283
Clinical Characteristics of Metabolic Associated Fatty Liver Disease
NCT06325254
Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease
NCT00868933
Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies
NCT06135584
Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD
NCT02285218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MAFLD and Non-MAFLD
non-invasive method, Fibroscan
Liver Ultrasound and transient elastography (FibroScan®)
Steatosis and Non-Steatosis
non-invasive method, Fibroscan
Liver Ultrasound and transient elastography (FibroScan®)
Fibrosis and Non-Fibrosis
non-invasive method, Fibroscan
Liver Ultrasound and transient elastography (FibroScan®)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
non-invasive method, Fibroscan
Liver Ultrasound and transient elastography (FibroScan®)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* underwent the laboratory tests, hepatic ultrasonography, and valid transient elastography (FibroScan) examination
Exclusion Criteria
* pre-existing active cancer, renal dysfunction, severe liver dysfunction, congestive heart failure or free abdominal fluid
* history of hyperthyroidism or hypothyroidism, pituitary diseases, and other types of diabetes
* significant alcohol consumption
* pregnancy
* receiving any therapeutic methods that could lead to liver steatosis or fibrosis, influence the glucolipid metabolism, or PRL levels, such as lipid-lowering, and PRL-lowering agents (bromocriptine) within 6 months prior to this study.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shen Qu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shen Qu
Principle investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.